Iterum Therap | 8-K: FY2025 Q3 Revenue: USD 390 K

Revenue: As of FY2025 Q3, the actual value is USD 390 K.

EPS: As of FY2025 Q3, the actual value is USD -0.2, missing the estimate of USD -0.09.

EBIT: As of FY2025 Q3, the actual value is USD -8.406 M.

Segment Revenue

• Net product revenues for the third quarter of 2025 were $0.4 million, related to sales of ORLYNVAH™, which launched in August 2025.

Operational Metrics

• Net loss for the third quarter of 2025 was - $9.0 million compared to a net loss of - $6.1 million for the same period in 2024.
• Non-GAAP net loss for the third quarter of 2025 was - $7.3 million compared to a non-GAAP net loss of - $4.8 million for the same period in 2024.
• Research and development expenses for the third quarter of 2025 were - $1.3 million, a decrease from - $3.1 million in the same period of 2024.
• Selling, general, and administrative expenses for the third quarter of 2025 were - $6.5 million, an increase from - $1.8 million in the same period of 2024.

Cash Flow

• Cash and cash equivalents were $11.0 million as of September 30, 2025.

Unique Metrics

• Cost of sales expense for the third quarter of 2025 was - $0.02 million, primarily consisting of royalty payments to Pfizer Inc.
• Amortization of intangible asset for the third quarter of 2025 was - $0.3 million, related to a regulatory milestone payment to Pfizer.

Outlook / Guidance

• Iterum expects net product sales of ORLYNVAH™ to range between $5 million and $15 million in 2026, depending on uptake and payer coverage.
• The company anticipates that its cash and cash equivalents, along with net proceeds from its at-the-market offering program, will be sufficient to fund operations into the second quarter of 2026.